Sarah J. Welsh

6.6k total citations · 2 hit papers
69 papers, 4.5k citations indexed

About

Sarah J. Welsh is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Sarah J. Welsh has authored 69 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 24 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Sarah J. Welsh's work include Renal cell carcinoma treatment (24 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Renal and related cancers (13 papers). Sarah J. Welsh is often cited by papers focused on Renal cell carcinoma treatment (24 papers), Cancer, Hypoxia, and Metabolism (14 papers) and Renal and related cancers (13 papers). Sarah J. Welsh collaborates with scholars based in United Kingdom, United States and Netherlands. Sarah J. Welsh's co-authors include Garth Powis, Eric C. Freundt, Michael J. Lenardo, Li Yu, Eric H. Baehrecke, Ryan Williams, Helen C. Su, Ajjai Alva, Parmesh Dutt and Pippa Corrie and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Sarah J. Welsh

68 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8

2004 1.0k citations Li Yu, Ajjai Alva et al. Science profile →
Autophagic programmed cell death by selective catalase degradation

2006 561 citations Li Yu, Fengyi Wan et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Sarah J. Welsh

Since Specialization

Citations

This map shows the geographic impact of Sarah J. Welsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah J. Welsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah J. Welsh more than expected).

Fields of papers citing papers by Sarah J. Welsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah J. Welsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah J. Welsh. The network helps show where Sarah J. Welsh may publish in the future.

Co-authorship network of co-authors of Sarah J. Welsh

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah J. Welsh. A scholar is included among the top collaborators of Sarah J. Welsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah J. Welsh. Sarah J. Welsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	K-Means Clustering of Hyperpolarised 13C-MRI Identifies Intratumoral Perfusion/Metabolism Mismatch in Renal Cell Carcinoma as the Best Predictor of the Highest Grade 2025 ·Cancers ·(unknown), (unknown), Mary A. McLean, João Duarte, Eva Serrão, Stephan Ursprung, Joshua Kaggie, Andrew B. Gill, Andrew N. Priest, Mireia Crispin‐Ortuzar, Anne Y. Warren, Sarah J. Welsh, Thomas J. Mitchell, Grant D. Stewart, Ferdia A. Gallagher	1
2	High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades 2024 ·European Radiology Experimental ·(unknown), (unknown), Andrew N. Priest, (unknown), Andrew B. Gill, Iosif Mendichovszky, Susan Francis, Anne Y. Warren, Brent O’Carrigan, Sarah J. Welsh, James O. Jones, Antony C. P. Riddick, James N. Armitage, Thomas J. Mitchell, Grant D. Stewart, Ferdia A. Gallagher	1
3	Multiarm, non-randomised, single-centre feasibility study—investigation of the differential biology between benign and malignant renal masses using advanced magnetic resonance imaging techniques (IBM-Renal): protocol 2024 ·BMJ Open ·(unknown), Mary A. McLean, (unknown), Marta Wylot, Joshua Kaggie, (unknown), Andrew B. Gill, João Duarte, M. Locke, Iosif Mendichovszky, (unknown), Andrew N. Priest, Anne Y. Warren, Sarah J. Welsh, James O. Jones, James N. Armitage, Thomas J. Mitchell, Grant D. Stewart, Ferdia A. Gallagher	2
4	Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study 2023 ·JHEP Reports ·Edmond Atallah, Sarah J. Welsh, Brent O’Carrigan, (unknown), (unknown), Andrew Kerr, (unknown), Colin Y.C. Lee, Colin Crooks, (unknown), (unknown), Ankit Rao, Hester Franks, (unknown), Guruprasad P. Aithal	24
5	‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors 2022 ·The Journal of Pathology ·Ashray Gunjur, (unknown), Oliver Klein, Andreas Behren, Trevor D. Lawley, Sarah J. Welsh, David J. Adams	10
6	Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials 2021 ·British Journal of Cancer ·Helen Mossop, Michael J. Grayling, Ferdia A. Gallagher, Sarah J. Welsh, Grant D. Stewart, James Wason	1
7	Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma 2021 ·PLoS ONE ·Stephan Ursprung, Andrew N. Priest, Fulvio Zaccagna, Wendi Qian, Andrea Machin, Grant D. Stewart, Anne Y. Warren, Timothy Eisen, Sarah J. Welsh, Ferdia A. Gallagher, Tristan Barrett	4
8	Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth 2021 ·Nature Communications ·Hafsa Munir, James O. Jones, Tobias Janowitz, Markus Hoffmann, Maximilien Euler, Carla P. Martins, Sarah J. Welsh, Jacqueline D. Shields	129
9	1138P Delayed immune-related adverse events (irAEs) on anti-PD1-based therapy 2020 ·Annals of Oncology ·C. Owen, Xue Bai, Thuan Chong Quah, Serigne Lo, (unknown), Clara Martínez-Vila, Prachi Bhave, Irene L. M. Reijers, Camille L. Gérard, (unknown), Wen Xu, Sarah J. Welsh, Shahneen Sandhu, Joanna Mangana, Jennifer L. McQuade, Paolo A. Ascierto, Lisa Zimmer, Douglas B. Johnson, Célèste Lebbé, Alexander M. Menzies	2
10	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients 2017 ·Biomarker Research ·Su Yin Lim, Jenny Lee, Sarah J. Welsh, Seong Beom Ahn, Edmond J. Breen, Alamgir Khan, Matteo S. Carlino, Alexander M. Menzies, Richard Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos	30
11	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? 2016 ·European Journal of Cancer ·Sarah J. Welsh, Helen Rizos, Richard A. Scolyer, Georgina V. Long	161
12	The clinical use of granulocyte-colony stimulating factor 2014 ·British Journal of Hospital Medicine ·(unknown), Sarah J. Welsh	5
13	Management of the patient with neutropenic sepsis 2012 ·British Journal of Hospital Medicine ·Sarah J. Welsh, Sandra J. Strauss	2
14	Assessment of the patient with neutropenic sepsis 2012 ·British Journal of Hospital Medicine ·Sarah J. Welsh, Sandra J. Strauss	1
15	A novel series of G-quadruplex ligands with selectivity for HIF-expressing osteosarcoma and renal cancer cell lines 2012 ·Bioorganic & Medicinal Chemistry Letters ·Caterina M. Lombardo, Sarah J. Welsh, Sandra J. Strauss, (unknown), Alan K. Todd, Rupesh Nanjunda, W. David Wilson, Stephen Neidle	27
16	Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α 2008 ·Molecular Cancer Therapeutics ·Mei Yee Koh, Taly R. Spivak-Kroizman, Sara Venturini, Sarah J. Welsh, Ryan Williams, D. Lynn Kirkpatrick, Garth Powis	242
17	Autophagic programmed cell death by selective catalase degradation breakdown → 2006 ·Proceedings of the National Academy of Sciences ·Li Yu, Fengyi Wan, Sudeshna Dutta, Sarah J. Welsh, Zhihua Liu, Eric C. Freundt, Eric H. Baehrecke, Michael J. Lenardo	561
18	Regulation of an ATG7 - beclin 1 Program of Autophagic Cell Death by Caspase-8 breakdown → 2004 ·Science ·Li Yu, Ajjai Alva, Helen C. Su, Parmesh Dutt, Eric C. Freundt, Sarah J. Welsh, Eric H. Baehrecke, Michael J. Lenardo	1023
19	Big brother is watching you--the ethical implications of electronic surveillance measures in the elderly with dementia and in adults with learning difficulties 2003 ·Aging & Mental Health ·Sarah J. Welsh, Angela Hassiotis, (unknown), Martin Deahl	80
20	The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition 2001 ·British Journal of Cancer ·(unknown), Sarah J. Welsh, Ann L. Jackman, G. Wynne Aherne	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact